INTRODUCTION
Protein phosphatase 2A (PP2A) is a major serine\threonine phosphatase implicated in cell-cycle progression, responses to signalling, cell transformation and cell differentiation [1, 2] . Apart from its apparent phosphoserine\threonine phosphatase activity, PP2A also exhibits low but detectable phosphotyrosine phosphatase (PTPase) activity [3, 4] . There is evidence that this PTPase activity may be physiologically relevant. For example, it was observed that the dimeric form of PP2A (PP2A D ) complexed with polyoma middle T\small t displays elevated PTPase activity [5] , suggesting that the intrinsic PTPase activity of PP2A D is stabilized by middle T\small t. Moreover, PP2A can autodephosphorylate and re-activate itself after phosphorylation on Tyr$!( [6] [7] [8] . In itro the PTPase activity of PP2A D can be upregulated specifically by a protein called PTPA (PTPase activator) [9] [10] [11] . PTPA can modulate PP2A D activity only in the presence of ATP\Mg# + . The exact mechanism of activation is not clear, although phosphorylation can be ruled out [9, 12] . PTPA has been cloned from rabbit and human cDNA libraries [12] , and homologues have been found in Xenopus, Drosophila, Saccharomyces cere isiae and Schizosaccharomyces pombe [13] . An alignment of these different PTPA clones reveals highly conserved Abbreviations used : CMV, cytomegalovirus ; EMSA, electrophoretic mobility shift assay ; GST, glutathione S-transferase ; NFI/CTF, nuclear factor I/CCAAT binding transcription factor ; PP2A, protein phosphatase type 2A ; PP2A D , dimeric form of PP2A ; PTPase, phosphotyrosine phosphatase ; PTPA, PTPase activator ; Sp1, specificity protein 1 ; UTR, untranslated region ; YY1, Yin Yang 1. 1 To whom correspondence should be addressed (e-mail jozef.goris!med.kuleuven.ac.be) The complete PTPA promoter sequence (nt k2681 to j207) has been deposited in the Genbank/EMBL/DDBJ Nucleotide Sequence Databases under accession number AF134185.
of a Yin Yang 1 (YY1) binding motif at positions k52 to k44. Binding of YY1 to this sequence is demonstrated in bandshift and DNase I footprinting experiments. Another YY1 binding motif is found in the 5h untranslated region, at positions j27 to j35. Mutations in either of these sites, abolishing YY1 binding in itro, have differential effects on promoter activity. Point mutations in both sites completely abolish promoter activity. Moreover, induction of promoter activity by co-transfection with a YY1 expression plasmid is fully dependent upon the presence of both intact YY1 binding sites. Thus YY1 apparently mediates basal transcription of the human PTPA gene through two binding sites within its proximal promoter. regions of amino acids, which are essential for PTPA activity [13] . Its ubiquitous and high expression in diverse mammalian tissues and cell lines [14] and its apparent high conservation throughout evolution point to an important function for this protein.
So far, no regulation of PTPA itself has been described. In order to investigate possible regulation at the transcriptional level, Van Hoof et al. [15] cloned the human PTPA gene, determined its transcriptional start site and started the analysis of part of its 5h flanking sequence to investigate its potential as a promoter. We have now further isolated and sequenced about 3 kb of this 5h upstream region and analysed the whole promoter region more in detail. We found that, in agreement with its ubiquitous expression, the PTPA gene promoter displays several features characteristic of housekeeping genes. The functionality of the promoter was analysed in transfection experiments with chimaeric luciferase reporter gene plasmids in three different cell types. By deletion mapping, a sequence essential for core promoter activity was identified. Using mutational analysis, cotransfection experiments and in itro DNA binding assays, we demonstrated that this sequence contains a functional binding site for transcription factor Yin Yang 1 (YY1). Interestingly, another YY1 binding motif was found in the 5h untranslated region (UTR), which also seems to contribute, although to a lesser extent, to in i o promoter activity. Thus we show that YY1 acts as a positive regulator of PTPA gene expression.
EXPERIMENTAL Isolation and sequencing of PTPA upstream sequences
The genomic clones HA and HF, both containing the PTPA upstream sequences [15] , were analysed by sequential restriction digestions and Southern blotting. The restriction fragments generated were mapped by hybridization with oligonucleotide probes (5h-end-labelled with T4 polynucleotide kinase and [γ-$#P]ATP) that were complementary to previously mapped DNA fragments of known composition. The fragments of interest were cloned into pBluescript II SKj (Stratagene) or pGEM-7Zf(j) (Promega) vectors and sequenced by the dideoxy-chain-termination method [16] using the T7 DNA Polymerase Sequencing kit (Pharmacia) with either T3, T7 and SP6 primers or specific internal primers.
Preparation of genomic DNA and Southern blotting for methylation analysis
High-quality genomic DNA was isolated from liver HepG2 cells as described by Majumdar et al. [17] . A 30 µg sample of DNA was double-digested with SacI\NaeI, SacI\NarI or SacI\EagI, or with SacI alone as a control. Electrophoresis was conducted on 0.8 % (w\v) agarose gels, and transfer to a Zeta-Probe Membrane (Bio-Rad) was carried out by vacuum blotting. The membrane was hybridized with a T4 polynucleotide kinase $#P-labelled oligonucleotide corresponding to nt k1870 to k1827 (5h-TTTGAATGAGCAGGTCCAGGGGACTCTGGGCAA-GTCCCTCCT TG-3h) at 60 mC for 24 h. Washing was performed as described by Sambrook et al. [18] . 
Nucleotides in bold indicate the point mutations introduced.
Construction of reporter plasmids
A 1 kb ApaI fragment containing 648 bp of the 5h flanking sequence, the complete first exon and part of the first intron was subcloned into pBluescript II SKj. Digestion with PstI\XhoI and treatment with exonuclease III (Erase-a-Base kit ; Promega) generated a 3h deletion and removed the PTPA start codon. The resulting fragment, comprising bases k648 to j38, was cloned into pGEM-7Zf(j) as a KpnI\SacI fragment. Treatment of this construct with SacI, the Klenow fragment of Escherichia coli DNA polymerase I (Klenow polymerase) and XhoI generated a fragment that could be cloned into the pGL2-Basic vector (Gene Light Plasmid ; Promega) treated with HindIII, Klenow polymerase and XhoI. The resulting luciferase reporter construct was named k648\j38-pLuc. Digestion of k648\j38-pLuc with SacI\XhoI, treatment with exonuclease III (Erase-a-Base) and subsequent re-ligation generated a set of 5h-deleted reporter constructs, comprising k394\j38 bp and k102\j38 bp respectively. Digestion of this construct with SphI and treatment with Klenow polymerase and HindIII generated a small fragment that could be inserted in the SmaI\HindIII-treated pGL2-Basic vector. This construct was named k67\j38-pLuc. The shortest reporter construct (k39\j38-pLuc) was made by digesting k648\j38-pLuc with SmaI and autoligating the remaining plasmid. Two longer reporter constructs were made by subcloning the 1.8 kb SacI\ApaI and the 0.8 kb NheI\ApaI genomic fragments into k648\j38-pLuc, resulting in a k2356\j38-pLuc and a k1565\j38-pLuc construct respectively. All constructs generated were confirmed by sequencing.
Cell culture
All cell lines were purchased from the American Type Culture Collection (Rockville, MD, U.S.A.). HepG2 cells (human liver hepatoma) and L929 cells (murine lung fibroblasts) were cultured at 37 mC and 5 % CO # in Dulbecco's modified Eagle's medium (Gibco\BRL), supplemented with 10 % (v\v) fetal calf serum (Gibco\BRL), 2 mM -glutamine (Gibco\BRL), 100 units\ml penicillin and 100 mg\ml streptomycin (Gibco\BRL). Saos-2 cells (human osteosarcoma) were cultured in McCoy's 5A medium (Gibco\BRL) supplemented with 15 % (v\v) fetal calf serum, 100 units\ml penicillin and 100 mg\ml streptomycin, at 37 mC and 5 % CO # .
Transient transfection assays
Transient transfections were performed in six-or 24-well dishes using Fugene reagent (Boehringer) or calcium phosphate\DNA co-precipitation as described by Sambrook et al. [18] . The pGL2-Promoter plasmid (Promega), containing the simian virus 40 promoter, and the promoterless pGL2-Basic vector were used as positive and negative controls respectively in separate but parallel assays. To evaluate transfection efficiencies, cells were co-transfected with a reporter vector containing the β-galactosidase gene driven by the cytomegalovirus (CMV) promoter. The amount of co-transfected DNA was one-tenth of the total DNA used in the transfection. At 48 h after transfection, cells were harvested in 250 or 100 µl of passive lysis buffer (Promega). Protein concentrations were measured using the bicinochoninic acid system (Pierce). After concentration adjustment, luciferase activity was measured with the Luciferase Assay System (Promega) according to the manufacturer's protocol using a MicroLumat LB96P (Berthold) with automated injection. Reagents for measurement of β-galactosidase activity were obtained from Tropix. For each construct at least two different DNA preparations (QIAGEN) were tested, and each transfection was repeated at least three times.
Electrophoretic mobility shift assays (EMSAs)
Nuclear extracts of cultured cells (L929 and HepG2) were prepared as described by Dignam et al. [19] . Bacterial expression, purification and thrombin cleavage of YY1-GST fusion proteins (where GST is glutathione S-transferase) in the pGEX-system (Pharmacia) were performed according to the manufacturer's instructions. The protein was found to be 80 % pure on Coomassie Blue-stained SDS\PAGE gels.
Complementary synthetic DNA oligonucleotides (Table 1) For competition experiments, at this point the appropriate unlabelled double-stranded DNA competitor oligonucleotides were included in the reaction mixture. Then 1-5 µg of nuclear extract or 10-100 ng of purified recombinant protein was added and the incubation was continued for 30 min at room temperature. For supershift analysis, 10 µl of anti-YY1 antibody or 10 µl of preimmune serum (TransCruz Supershift Reagent ; Santa Cruz Biotechnology) was added 15 min after protein addition, and incubation was continued overnight at 4 mC. Samples were analysed on non-denaturing 5 % (w\v) polyacrylamide gels in 0.5iTBE (1iTBE l 45 mM Tris\ borate\1 mM EDTA)\0.05 % Triton. After electrophoresis, gels were dried and bands were visualized by autoradiography.
In vitro DNase I footprinting
The DNA fragment used was a HindIII\PstI restriction fragment from a pBluescript II SKj construct, containing the k60\j50 fragment of the minimal PTPA promoter, cloned in the EcoRV restriction site in the sense direction. The k60\j50 fragment was generated by ' hCG ' PCR [22] with PWO polymerase (Boehringer), using two specific primers (5h-CCCGCACTGAC-ATGGCCGTCGCCCGGGTCCGC-3h and 5h-CACAGCGAA-GACGGCCGCCATGTCGG-3h) and the HF genomic clone as template. The use of this particular PCR technique was necessary because of the high GC content of the sequence. End-labelling of the fragment (in this case in the sense strand) was done by a Klenow polymerase fill-in reaction of the HindIII site in the presence of [α-$#P]dATP and [α-$#P]dCTP. For the footprinting reactions, 50 000-100 000 c.p.m. of radiolabelled probe was incubated for 20 min at 20 mC in 50 µl of binding mixture containing 8.5 % glycerol, 50 mM NaCl, 2.5 mM MgCl # , 10 mM Hepes, 0.05 mM EDTA, 2 % polyvinyl alcohol, 20 ng\µl poly(dI\dC), 1 mM dithiothreitol and different amounts of recombinant thrombin-cleaved YY1-GST. Different dilutions of DNase I (Boehringer) in 10 mM CaCl # and 12.5 mM MgCl # were added and the incubation was continued for exactly 1 min. The reaction was stopped by adding 100 µl of DNase I stop solution (1 % SDS, 200 mM NaCl and 20 mM EDTA). When competition assays were performed, 5-10 pmol of competitor DNA was added in the binding mixture and the DNase I incubation was prolonged slightly (for 10-15 s). After phenol\chloroform ex-traction and ethanol precipitation, the samples were washed, dried and subjected to electrophoresis on 8 % (w\v) denaturing (7 M urea) polyacrylamide gels in 0.5i TBE. Gels were fixed in 10 % (v\v) acetic acid, washed, dried and exposed. As sequence reference, a guanine-specific chemical cleavage reaction was performed on the same probe as described by Maxam and Gilbert [23] .
Site-directed mutagenesis
To introduce point mutations into the YY1 binding sites in the context of the k102\j38-pLuc plasmid, standard PCR techniques were not suitable because of the high GC content and sequence repetitiveness of the promoter region. Therefore another approach was chosen. Five pairs of complementary and partially overlapping synthetic DNA oligonucleotides, some containing the desired mutations (Table 2) , were phosphorylated by T4 polynucleotide kinase (Pharmacia), denatured, annealed and ligated. The resulting fragments were then ligated into pGL2-Basic digested with NheI\KpnI and named k102\j38 YY1(u)mut-pLuc, k102\j38 YY1(d)mut-pLuc and k102\ j38 YY1(u,d)mut-pLuc [in these plasmids the upstream (u), the downstream (d) or both YY1 sites are mutated]. Sequencing of the constructs confirmed the introduction of the different mutations.
RESULTS

Further isolation and sequence analysis of the 5h flanking region of the human PTPA gene
We analysed the genomic clones HA and HF, known to contain the upstream sequences of the PTPA gene [15] , by Southern blotting, as described in the Experimental section. Fragments of these clones, containing the known extreme 5h end of the PTPA gene, were subsequently cloned and sequenced. Analysis of the complete DNA sequence from nt k2681 to j207 (Genbank accession no. AF134185) revealed the presence of several potential binding sites for transcription factors. No consensus CAAT or TATA boxes are present in the correct position relative to j1 and, unlike many other TATA-less promoters, no pyrimidine-rich initiator binding site [5h (C\T)(C\T)A +" N(A\T) (C\T)(C\T) 3h] is present either [24] . Potentially important transcription factor binding sites include some that play a role in cell proliferation and differentiation, such as those for E2A (Ebox family), Ets-1, ELP (embryonal long terminal repeat binding protein), MAF (mammary activating factor) and PEA3 (polyoma enhancer factor 3) (Pu-box family), glucocorticoid response element (GRE) and peroxisome-proliferator-activated receptor (PPAR) (nuclear receptor family), YY1, Myb, CCAAT enhancer binding protein (C\EBP), p53 and activator protein-1 (AP-1). However, the majority of the transcription factor binding sites detected are very GC-rich [including potential Sp1 (specificity protein 1)\Sp3, Krox-24\EGR-1 (early growth response gene product 1), GCF (GC factor) and AP-2 (activator protein-2) sites], reflecting the high GC content of the promoter, another well known characteristic of many TATA-less genes [25] .
Identification of an unmethylated CpG island in the proximal promoter region
The apparent high GC content of the promoter prompted us to evaluate the sequence for the presence of CpG islands. CpG islands contain unusually high contents of CpG dinucleotides, which occur very rarely in vertebrate DNA. They are commonly defined as DNA regions of at least 200 bp in length with an average GC content above 50 %, and a ratio of observed to expected CpG doublets of greater than 0.6 [26] . They coincide frequently with the 5h ends of housekeeping genes and of some tissue-specific genes, and are postulated to constitute sites of interaction between transcription factors and promoters [27] . Normally, they remain unmethylated, and their aberrant methylation has been shown to promote transcriptional inactivation [28] .
Statistical analysis of the PTPA promoter region revealed a putative CpG island with an average GC content of 71 % and an observed\expected CpG frequency of up to 7 between nt k158 and j91 ( Figure 1A ). Its methylation state was checked by digesting genomic DNA, extracted from PTPA-expressing HepG2 cells, with three methylation-sensitive restriction enzymes (NarI, NaeI and EagI), and with SacI as a 5h limiting enzyme. Since NarI, NaeI and EagI sites are only present within the CpG island and not in the rest of the promoter region, we may expect to detect a fragment of approx. 2.2 kb with a promoter-specific probe if the sequence is not methylated. However, if the sequence is methylated, we should see a larger fragment (max. 8 kb), the size of which will depend upon the presence of NarI, NaeI and Yin Yang 1 positively regulates phosphotyrosine phosphatase activator gene The promoter fragments have their 3h ends at j38 and their 5h ends at respectively k2356, k1565, k648, k394, k102, k67 and k39 nt relative to the transcription initiation site (a schematic representation of the deletion constructs is shown on the left). The measured values were first corrected for endogenous luciferase activity by subtraction of the blank (luciferase activity of untransfected cells) and subsequently for differences in transfection efficiency by adjusting them to the average β-galactosidase value of all the samples in the same transfection experiment. The reported values are relative corrected activities of the promoter constructs compared with the corrected activity of k2356/j38-pLuc, which was set at 100 %. For each value, the S.E.M. of at least three independent experiments is indicated.
EagI restriction sites downstream of the CpG island. The results of the Southern blot clearly indicate that the sequence is not methylated, since a fragment of approx. 2.2 kb was detected with all three methylation-sensitive enzymes ( Figure 1B) . Consequently, in HepG2 cells the PTPA gene contains an active unmethylated CpG island in the proximal promoter region (nt k158\j91).
Functional delineation of the minimal human PTPA gene promoter
To localize the region essential for transcriptional activity, we generated a set of chimaeric constructs containing different genomic fragments of the human PTPA gene fused to a luciferase reporter gene. These constructs were transfected into human liver HepG2 cells, murine lung L929 cells and human bone Saos-2 cells, along with a CMV\β-galactosidase expression vector as an internal control for varying transfection efficiencies within one cell line. Luciferase and β-galactosidase activities were measured 48 h later. In none of these three PTPA-expressing cell lines could significant differences be observed between the luciferase activities of k2356\j38-pLuc, k1565\j38-pLuc, k648\j38-pLuc, k394\j38-pLuc, k102\j38-pLuc and k67\j38-pLuc (Figure 2) . In L929 cells, overall promoter activities seemed to be somewhat lower than in Saos-2 and HepG2 cells, but these differences can probably be explained in terms of different transfection efficiencies among different cell lines. However, the severe decrease in luciferase activity of the k39\j38-pLuc plasmid compared with that in the longer reporter constructs (Figure 2 ) was consistent in all cell lines, indicating that the region between nt k67 and nt k39 is crucial for basal expression of the human PTPA gene. Interestingly, this region coincides remarkably well with the determined CpG island.
YY1 binds to the promoter region essential for promoter activity
Between nt k67 and k39, the region essential for promoter activity (see above), two well-conserved consensus transcription factor binding sites are present : a perfect (9\9) YY1 binding site at positions k52\k44 and an imperfect (11\14) nuclear factor I\CCAAT binding transcription factor (NFI\CTF) binding site at positions k49\k36. To assess whether these sites constitute real transcription factor binding sites, bandshift assays (EMSAs) were performed with a synthetic oligonucleotide comprising nt k60\k25 of the PTPA promoter [PTPA-YY1(u) ; Table 1 ] and nuclear extracts of L929 cells.
First, it was shown that these extracts contain functional NFI\CTF and YY1 ( Figure 3A) . Incubation of oligonucleotides containing known NFI\CTF and YY1 binding sites (NFI-CON and YY1-CON respectively ; Table 1 ) with these extracts resulted in two clear retarded complexes of different electrophoretic mobility. Therefore it is clear that both transcription factors are present in our L929 extracts and that both can bind to their respective control probes under the experimental conditions used.
Upon incubation of the PTPA-YY1(u) probe with these extracts under the same conditions, a clear retarded band could be observed ( Figure 3B, lane 4) , which could be competed by an excess of unlabelled PTPA-YY1(u) (lanes 7 and 8) and by an excess of unlabelled YY1-CON (lanes 5 and 6), but not by an excess of NFI-CON (results not shown). Furthermore, incubation of radiolabelled YY1-CON with the same extracts resulted in a retarded complex (lane 2) that obviously co-migrated with the observed PTPA-YY1(u) binding complex (lane 4), whereas the complex formed on NFI-CON migrated significantly more slowly ( Figure 3A) .
In order to confirm whether YY1 indeed interacts with its candidate YY1 binding site at positions k52\k44, EMSAs were CON (lanes 1 and 2) and YY1-CON (lanes 3 and 4) contain known binding sites for NFI/CTF and YY1 respectively (see also Table  1 ). In lanes 2 and 4, 2 µg of L929 nuclear extract was added. Lanes 1 and 3 are controls without protein addition. (B) Labelled oligonucleotides are indicated below the lanes : YY1-CON (lanes 1 and 2), PTPA-YY1(u), containing nucleotides k60/k25 of the PTPA promoter (lanes 3-10), and PTPA-YY1(u)MUT, identical to PTPA-YY1(u) except for two point mutations in the core sequence of the putative YY1 binding site at nt k52/k44 (lanes 11 and 12). Lanes 1, 3 and 11 are controls without L929 nuclear extracts. In lanes 2, 4 and 12 no competitor DNA was added. In lanes 5-10 a 200-fold or 100-fold molar excess of unlabelled competitor DNA was added (indicated above the gel) : the consensus YY1 oligonucleotide (lanes 5 and 6), PTPA-YY1(u) itself (lanes 7 and 8) or the mutated oligonucleotide PTPA-YY1(u)MUT (lanes 9 and 10).
performed with PTPA-YY1(u)MUT. This oligonucleotide is identical to PTPA-YY1(u), except for two point mutations in the putative YY1 binding site, which destroy its 5h-CATN-3h binding core [29] in both strands (G −&# ACATGGCC −%% was mutated to G −&# AAATTGCC −%% ) ( Table 1 ). In contrast with wild-type PTPA-YY1(u), no retarded complex could be observed with PTPA-YY1(u)MUT ( Figure 3B, lane 12) . In addition, an excess of unlabelled PTPA-YY1(u)MUT failed to compete with labelled PTPA-YY1(u) for the PTPA-YY1(u) binding protein ( Figure 3B, lanes 9 and 10) . Taken together, these data strongly support the presence of a YY1 binding site in the minimal PTPA promoter at positions k52\k44.
Identification of a second YY1 binding site in the 5h UTR
Examination of the complete proximal promoter sequence between nt k67 and j38 revealed the presence of a second putative YY1 binding motif at nt j27\j35, again perfectly matching the YY1 consensus sequence. As for the upstream YY1 binding site, we assessed whether YY1 could bind to this site in bandshift assays. For this purpose, a synthetic oligonucleotide, comprising nt k8\j41 of the PTPA promoter [PTPA-YY1(d) ; Table 1 ], was labelled and incubated with L929 nuclear extracts. A clear retarded band could be observed that disappeared upon addition of unlabelled YY1-CON and unlabelled PTPA-YY1(d) (results not shown). Following the same approach as for the identification of the upstream YY1 site, we next introduced similar point mutations in the downstream YY1 site : G +#( AC-ATGGCG +$& was mutated to G +#( AAATTGCG +$& ( Table 1) . The resulting mutated oligonucleotide, PTPA-YY1(d)MUT, not only failed to bind YY1, but also failed to compete with labelled PTPA-YY1(d) for protein binding (results not shown).
To confirm the former data, bandshifts were performed with a PTPA-promoter-specific probe, comprising nt k60\j50 and thus containing both putative YY1 binding sites. In the presence of low L929 protein concentrations, binding complexes were formed in which only one YY1 site was occupied (one retarded band was seen), whereas in the presence of high protein concen-
Figure 4 Supershifts of PTPA promoter binding complexes with YY1-specific antibodies
A probe containing nt k60/j50 of the PTPA promoter was incubated without (lane 1) or with (lanes 2-4) 10 µg of L929 nuclear extract. In lane 3, 10 µl of a polyclonal antibody specific for YY1 (α-YY1 Ab) was added. Lane 4 is a control to which the same amount of preimmune serum was added. In lane 5 the probe was incubated with 10 µl of anti-YY1 antibody without L929 extracts. The retarded complexes in the absence of antibody are indicated by arrows, whereas the arrowheads indicate the complexes formed in the presence of antibody.
trations the second site became occupied by YY1 as well (two retarded bands were seen). In both cases the specificity of protein binding was confirmed in competition assays with unlabelled YY1-CON (results not shown).
Supershift assays with YY1-specific antibodies
To further confirm the identity of the binding protein as being YY1, we performed supershift experiments with the k60\j50 PTPA-promoter-specific probe, L929 nuclear extracts and a polyclonal antibody specific for YY1 (Figure 4) . The two retarded complexes obtained by addition of relatively high amounts of 
Figure 6 Functional analysis of both YY1 binding sites
Transient transfections were performed in HepG2, L929 and Saos-2 cells with the constructs indicated on the left : k102/j38-pLuc is the wild-type construct, whereas k102/j38 YY1(d)mutpLuc, k102/j38 YY1(u)mut-pLuc and k102/j38 YY1(u,d)mut-pLuc contain two point mutations in the downstream (d), the upstream (u) or both YY1 binding motifs. Luciferase activities are presented as a percentage of the activity of k102/j38-pLuc, which was set at 100 %. MeanspS.E.M. of at least three independent experiments are indicated.
In vitro DNase I footprinting of the minimal PTPA promoter
To substantiate the former results, in itro DNase I footprinting experiments were performed. As protein source in this assay we used a recombinant version of human YY1, whose in itro binding capacity was first tested in a bandshift assay with YY1-CON, PTPA-YY1(u) and PTPA-YY1(d). Addition of the protein to these probes resulted in the formation of retarded complexes indistinguishable from the complexes obtained by using L929 nuclear proteins (results not shown).
When this recombinant YY1 was used in footprinting experiments with the k60\j50 PTPA probe, two regions protected from DNase I digestion appeared ( Figure 5, lanes 3-6) . Both windows disappeared upon addition of an excess of unlabelled YY1-CON competitor (lanes 8 and 9) , confirming the specificity of binding. Comparison with the G-specific sequencing reaction revealed that both protected regions contain the theoretical YY1 binding sites at nt k52\k44 and nt j27\j35, as expected. Thus these data confirm the presence of two YY1 binding sites in the PTPA promoter.
Functional analysis of the YY1 binding sites
To investigate the functional significance of the YY1 binding motifs, the k102\j38 YY1(u)mut-pLuc, k102\j38 YY1-(d)mut-pLuc and k102\j38 YY1(u,d)mut-pLuc plasmids were generated. In k102\j38 YY1(u)mut-pLuc and k102\j38 YY1(d)mut-pLuc, either the upstream (u) or the downstream (d) YY1 binding site is mutated : they contain the same two point mutations as described for PTPA-YY1(u) and PTPA-YY1(d) respectively. In k102\j38 YY1(u,d)mut-pLuc both YY1 binding sites are mutated.
First, these mutant PTPA promoter plasmids were tested in transient transfections in Saos-2, L929 and HepG2 cells in parallel with the wild-type k102\j38-pLuc construct ( Figure  6) . The results clearly demonstrate that mutation of the downstream YY1 binding site had minor effects on overall promoter activity (50-60 % of promoter activity remaining). Conversely, promoter activity fell dramatically after mutation of the upstream YY1 binding site (90 % decrease). This observation is in line with the results shown in Figure 2 , where a similar decrease in promoter activity was seen upon deletion of the YY1(u) site Transient transfections were performed with 1 µg of k102/j38-pLuc, k67/j38-pLuc, k39/j38-pLuc, k102/j38 YY1(u)mut-pLuc, k102/j38 YY1(d)mut-pLuc or k102/j38 YY1(u,d)mut-pLuc, together with various amounts of pCMV-YY1 or empty pCMV (200, 100 and 50 ng). Induction factors were calculated as the ratios of luciferase activities of pCMV-YY1-co-transfected/pCMV-co-transfected reporter plasmids, minus the induction factor of the empty pGL2-Basic reporter plasmid (which maximally reached a value of 2). MeanspS.E.M. of three independent experiments are indicated.
(compare activities of k67\j38-pLuc and k39\j38-pLuc). Finally, it is clear that PTPA promoter activity is completely abolished if both YY1 binding sites are mutated.
In a second experiment, we performed co-transfections of k102\j38-pLuc, k67\j38-pLuc, k39\j38-pLuc and the three mutated versions of k102\j38-pLuc with a CMVpromoter-driven YY1 expression plasmid (pCMV-YY1, a gift from T. Shenk) in Saos-2 cells (Figure 7) . Overexpression of YY1 resulted in induction of the observed promoter activities of k102\j38-pLuc and k67\j38-pLuc, whereas the activities of k39\j38-pLuc, k102\j38 YY1(u)mut-pLuc, k102\j38 YY1(d)mut-pLuc and k102\j38 YY1(u,d)mut-pLuc remained unaltered. Thus the YY1-inducibility of promoter activity clearly depends upon the presence of two intact YY1 binding sites (as in k102\j38-pLuc and k67\j38-pLuc), since deletion (as in k39\j38-pLuc) or mutation [as in k102\j38 YY1(u)mutpLuc] of the upstream site, mutation of the downstream site [as in k102\j38 YY1(d)mut-pLuc] or mutation of both sites [as in k102\j38 YY1(u,d)mut-pLuc] results in loss of transcriptional stimulation upon pCMV-YY1 co-transfection. Moreover, the apparent stimulation of PTPA promoter activity by YY1 seems proportionate to the amount of co-transfected pCMV-YY1, demonstrating the dose-dependency of the effect (Figure 7) . These results also indicate that, in Saos-2 cells, endogenous YY1 is not sufficient to saturate the introduced reporter constructs.
DISCUSSION
We have demonstrated that the human PTPA gene 5h flanking sequence displays many characteristics of a TATA-less housekeeping gene promoter, including the presence of a 250 bp long unmethylated CpG island spanning part of exon I (nt k158\j91). In addition, the overall GC content of the promoter region is high (62 % between nt k2681 and j210), reflected by the presence of many putative Sp1 binding sites.
In contrast with their established role in the regulation of many other housekeeping genes [25] , these Sp1 binding sites seemed not to be required for basal expression of the PTPA gene. Indeed, the minimal PTPA promoter was localized between nt k67 and j38, a region that lacks Sp1 consensus sequences. Moreover, co-transfection of an Sp1 expression vector with k67\j38-pLuc in SL2 Drosophila Schneider cells, which lack endogenous Sp1 [30] , did not result in any induction of the observed basal promoter activity (V. Janssens, unpublished work).
Instead, we demonstrated the functionality of two YY1 binding sites within the PTPA core promoter : one upstream site at positions k52\k44 and one downstream site at positions j27\j35. YY1 is a ubiquitously expressed multifunctional transcriptional regulator that can act as a repressor, an activator or an initiator element binding protein, depending on both the promoter and the cellular context (for a review, see [31] ). Both repression and activation domains have been identified within YY1, which provides a structural basis for its dual functionality [32, 33] . A large number of cellular and viral genes have been shown to be negatively regulated by YY1 (for reviews, see [31, 34] ). Examples of genes positively regulated by YY1 include c-myc [35] , some ribosomal protein genes [36] and p53 [37] .
With regard to the PTPA gene, our data strongly support an activating role for YY1. Indeed, in transient transfection experiments in Saos-2 cells, it was demonstrated that overexpression of YY1 could enhance PTPA promoter activity by 3-4 times, depending on the amount of co-transfected pCMV-YY1. Moreover, this activation apparently relied on the integrity of both YY1 sites, since mutation of either one of them abolished transcriptional stimulation by YY1. In addition, it was shown that mutation of both YY1 binding sites, which destroyed YY1 binding in itro, completely abolished promoter activity. Nevertheless, it seems that the distinct sites contribute differently to the observed basal promoter activity, since mutation (or deletion) of the upstream site alone resulted in a dramatic decrease in promoter activity, whereas mutation of the downstream site alone affected promoter activity only moderately. These differences in functionality might be explained in part by different binding affinities of YY1 for these sites in i o.
YY1 may activate PTPA transcription by two mechanisms : (i) as an initiator protein, binding to the transcriptional start point region, or (ii) as a ' classical ' transcription factor that modulates the basal transcription machinery by binding upstream and\or downstream of this initiator region. Considering that the unique PTPA transcription initiation site [15] is localized in between the two YY1 binding sequences, it seems more likely that YY1 activates the PTPA promoter by stimulating basal transcription and not by acting as an initiator.
Although YY1 is constitutively expressed, several mechanisms of direct or indirect regulation of YY1 activity have been published. Conflicting reports exist concerning the influence of CpG methylation on the binding capacity of YY1 to its cognate recognition site. Gaston and Fried [38] reported that binding of YY1 to the Surf-1\Surf-2 promoter is not affected by CpG methylation, whereas Satyamoorthy et al. [39] reported very poor binding of YY1 to CpG-methylated DNA. Since in the PTPA promoter the YY1 binding sites obviously reside within an unmethylated CpG island, this promoter may represent another interesting model to further clarify this issue.
In addition to these binding site modifications, the activity of YY1 can also be modulated by its interaction with other cellular proteins. The adenovirus E1A oncoprotein can both relieve YY1-mediated gene repression and enhance YY1-mediated gene activation, probably through indirect binding to YY1 via interaction with p300 [40] . The c-Myc protein can bind to YY1 as well, thereby inhibiting both its activating and its repressing abilities [41, 42] . YY1 has also been shown to interact with Sp1 [43, 44] . In the future it may be interesting to investigate whether these YY1-interacting and -regulating proteins have any influence on PTPA gene expression. Since many Sp1 sites are present upstream of the minimal PTPA promoter, it may be particularly
